The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis

@article{Levy2005TheVO,
  title={The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis},
  author={C. Levy and J. Lymp and P. Angulo and G. Gores and N. LaRusso and K. Lindor},
  journal={Digestive Diseases and Sciences},
  year={2005},
  volume={50},
  pages={1734-1740}
}
CA 19-9 has been used with questionable accuracy to aid diagnosis of cholangiocarcinoma complicating primary sclerosing cholangitis. We aimed to characterize the test properties of CA 19-9 and of a change in CA 19-9 over time in predicting cholangiocarcinoma. Charts of 208 patients were reviewed. Fourteen patients had cholangiocarcinoma. Median CA 19-9 was higher with cholangiocarcinoma (15 vs. 290 U/ml, p < 0.0001). A cutoff of 129 U/ml provided: sensitivity 78.6%, specificity 98.5%, adjusted… Expand
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis
TLDR
Tumor serology combined with cross‐sectional liver imaging may be useful as a screening strategy and cholangiography with cytologic examination is helpful for the diagnosis of cholangsiocarcinoma in patients with PSC. Expand
Increased Serum Levels of Carbohydrate Antigen 19-9 and Outcomes in Primary Sclerosing Cholangitis Patients Without Cholangiocarcinoma
TLDR
Thirty-two percent of patients with PSC had elevated serum CA 19-9 in the absence of CCA, and there was a trend towards shorter OLT-free survival in PSC patients with elevated CA-19-9. Expand
CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma
TLDR
Predictive factors for overall survival were identified, namely presence of metastasis, surgery, and chemotherapy, and CA 19-9 levels ≥103 U/L were predictive factors for survival and metastization. Expand
Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis
TLDR
Serum CA19-9 is a useful non-invasive biomarker for CCA detection and may become a clinically useful tool to identify high-risk patients. Expand
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma.
TLDR
Thirty-seven percent of patients with PSC who have serum levels of CA 19-9 greater than 129 U/mL do not have CCA, and additional studies should be performed to determine the outcomes of these patients. Expand
The value of serum CA19‐9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis
TLDR
The results showed that the CA19‐9 level in patients with PSC was significantly higher than that of patients diagnosed with other EIMs and it could be concluded that cut‐off of >129 U/mL may not be an accurate cut-off for the diagnosis of CCA in IBD patients. Expand
Carbohydrate Antigen 50: Values for Diagnosis and Prognostic Prediction of Intrahepatic Cholangiocarcinoma
TLDR
Serum CA50 levels were increased and associated with the severity of bile duct pathology and a higher level of CA50 was associated with poor clinical outcome and shorter survival in iCCA patients, suggesting CA50 can be a diagnostic and poor prognostic marker candidate for i CCA. Expand
The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience
TLDR
Brush cytology has moderate sensitivity in differentiating strictures in PSC patients and CA 19-9 has high sensitivity but bilirubin level can affect the CA19-9, therefore, advanced techniques and parameters are needed for detecting CCA in P SC patients. Expand
Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer.
TLDR
Elevated circulating CYFRA 21-1 is a specific, but less sensitive diagnostic marker than CA 19-9, predicts a poor outcome and may act as a surrogate marker of circulating tumor cells in BTC. Expand
Incidence, Diagnosis, and Therapy of Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis
TLDR
If tumors are small or incidental findings, liver transplantation leads to a 3- to 5-year survival rate of 35%. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis.
TLDR
The measurement of serum concentrations of CA 19-9 is a promising test for detecting cholangiocarcinoma in patients with PSC. Expand
CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation.
  • A. Fisher, N. Theise, +6 authors P. Sheiner
  • Medicine
  • Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 1995
TLDR
An elevated serum CA19-9 level in a patient with stage IV primary sclerosing cholangitis does not reliably predict coexisting cholangsiocarcinoma, and Persistently high or rising serum CA 19-9 levels do not indicate more urgent need for liver transplantation. Expand
Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: An analysis of the serological marker CA 19‐9
TLDR
The measurement of serum concentrations of CA 19‐9 is a promising test for detecting cholangiocarcinoma in patients with PSC. Expand
CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.
TLDR
Tumor markers as a diagnostic tool in diagnosing cholangiocarcinoma in patients with PSC are unfortunately not as valuable as previously reported. Expand
Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.
TLDR
A combination of serum tumor markers will identify most occult tumors and will improve selection of appropriate cases for orthotopic liver transplantation. Expand
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
  • D. Mann, R. Edwards, S. Ho, W. Lau, G. Glazer
  • Medicine
  • European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2000
TLDR
Confident discrimination between benign and malignant disease could not be made on the basis of a solitary elevated CA19-9 measurement, and Hyperbilirubinaemia was associated with a further deterioration in specificity and caution is warranted when interpreting the results in jaundiced patients. Expand
Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
TLDR
Screening patients with primary sclerosing cholangitis for cholangsiocarcinoma with CA19-9 and carcinoembryonic antigen is reasonable, but the ideal intervals at which to obtain these tests and the cost-effectiveness require further study. Expand
A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
TLDR
The serum tumor markers CEA, CA 19-9, CA 50 and CA 242 are of limited value for the detection of CC in patients with PSC because of low specificity, however, no falsely increased values in Patients with hyperbilirubinemia are found. Expand
The Effect of Benign and Malignant Liver Disease on the Tumour Markers CA19-9 and CEA
The serum concentrations of CA19-9 and carcinoembryonic antigen (CEA) were measured in 150 consecutive patients with histologically proven liver disease admitted to a liver unit for transplantExpand
Primary sclerosing cholangitis: a long-term follow-up study.
TLDR
The estimated survival curve in PSC was displaced to the left, indicating a reduced life expectancy of about 30 years, and the 50% survival since diagnosis of liver disease was calculated to be 17 years in patients with PSC and 50 years in a comparable group among the general population. Expand
...
1
2
3
...